Hep C And Other High-Cost Drugs Behind 10% Rise In Canadian Medicines Spend
Executive Summary
Public drug plan spending on medicines in Canada rose by nearly 10% in 2015-16, driven by a shift to the use of expensive patented drugs such as the direct acting antivirals for hepatitis C.